Company intelligence / Profile preview

Rosewind

USA

Ownership: Private
Development stage: Other

Overview

Prior to its merger into Aytu BioScience, Rosewind had successfully advanced its lead candidate Zertane (for premature ejaculation) through two Phase 3, two Phase 2, and two Phase 1 trials in Europe and was preparing a pivotal US study; its RedoxSYS System diagnostic held CE marking in Europe and Canadian approval and was actively used in clinical collaborations for male infertility studies

Therapeutic areas: Men's Health
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Strategic commercialization partners for Zertane in Canada, South Korea, South Africa, and Latin America

Beyond the preview

Go deeper on Rosewind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rosewind.

Explore the full profile